IHS examines the global experience with risk sharing agreements in recent conference presentation
Last week I presented, with IHS colleague Sarika Pundit, about the global experience with risk sharing agreements at the CBI Reimbursement and Contracting conference in Philadelphia. Among other things, we examined the trends in risk sharing agreements (known as patient access schemes (PAS) in some markets) and the growing prevalence of finance-based agreements. The therapeutic areas most likely to be affected by risk sharing were also reviewed, along with recent regulatory developments that could encourage greater utilisation of risk sharing deals. The analysis was based on the IHS Risk Sharing database and our Payer Partnerships Multi Client study, with additional insights provided from risk sharing coverage in our Same Day Analysis service, Special reports and the IHS International Reference Pricing (IRP) matrix. An abbreviated version of the presentation is available below.
Milena Izmirlieva is the head of the life sciences research team at IHS
Posted 3 March 2015
- The impact of Medicare coverage for anti-obesity interventions
- National Academies report adds fuel to fire in raging US drug pricing debates
- Amsterdam triumphs: Is the Netherlands a Trojan horse for pricing and drug approval reform in Europe?
- Will Argentina's public healthcare reform finally accelerate?
- Value in healthcare: Insights from ISPOR
- Better diabetes treatment can save Medicaid over $4 billion per year
- So, was this worth the wait?…the UK government finally responds to last year's Accelerated Access Review
- Visit us at ISPOR 2017 Glasgow!